sábado, 2 de febrero de 2019

Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations. - PubMed - NCBI

Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations. - PubMed - NCBI



 2018 Dec;151(3):489-493. doi: 10.1016/j.ygyno.2018.10.010. Epub 2018 Oct 10.

Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations.

Abstract

OBJECTIVE:

Estimate the prevalence of cardiovascular disease risk factors and endpoints in women with BRCA mutations.

METHODS:

Women, age 40 and older, with BRCA mutations identified in Kaiser Permanente Northern California completed a questionnaire and underwent a lipid and fasting glucose panel. Bivariable analysis of clinical and demographic factors was performed. The Atherosclerotic Cardiovascular Disease (ASCVD) calculator was used to predict 10-year risk of a cardiovascular event.

RESULTS:

Of the 233 women, 19 women had intact ovaries (median age 56.0) and 214 had undergone risk-reducing salpingo-oophorectomy (RRSO). Among the 108 women with RRSO under age 50 (median age 51.0), compared to the 106 women who had RRSO at or over age 50 (median age 63.5) 6.5% vs 10.4% reported diabetes (p = 0.30), 23.2% versus 28.3% had elevated fasting blood glucose (p = 0.39), 21.3% versus 34.0% reported hypertension (p = 0.04) with median systolic blood pressure of 118 mmHg versus 125.5 mmHg (p < 0.009), 25% versus 32% reported hyperlipidemia (p = 0.40), and 42% versus 49% had any abnormal lipid test (p = 0.28). An elevated 10-year ASCVD risk of over 10% was seen in 6.1% versus 24.8% respectively (p = 0.0001).

CONCLUSION:

Women who underwent RRSO at age of 50 and over, had higher ASCVD 10-year risk than women who underwent RRSO at younger ages most likely owing to older age at study entry. The ASCVD risks for women with BRCA mutation who had RRSO did not suggest increased risk associated with being a BRCA mutation carrier.

KEYWORDS:

BRCA mutations; Cardiovascular disease; Lipids; Oophorectomy

PMID:
 
30314670
 
DOI:
 
10.1016/j.ygyno.2018.10.010

[Indexed for MEDLINE]

No hay comentarios:

Publicar un comentario